Key result
Reduced hyperemic coronary flow velocity linked to ~560% higher major cardiovascular events risk in ANOCA with CFVR <2.5.
Why the study?
Risk stratification in patients with ANOCA remains suboptimal, and CFVR is susceptible to hemodynamic variability, prompting evaluation of whether hCFV improves risk prediction.
Does hyperemic coronary flow velocity (hCFV) improve risk prediction for MACE in patients with angina and nonobstructive coronary artery disease?
Cohort (n=381)
Does hyperemic coronary flow velocity (hCFV) improve risk prediction for MACE in patients with angina and nonobstructive coronary artery disease?
Reduced hyperemic coronary flow velocity provides incremental prognostic value beyond coronary flow velocity reserve for identifying high-risk patients with angina and nonobstructive coronary arteries.
Answers are grounded in this paper and cite their sources.
May better identify high-risk patients with angina and nonobstructive CAD; extends models beyond CFVR but remains hypothesis-generating.
Risk stratification in patients with angina and nonobstructive coronary arteries (ANOCA) remains suboptimal. Coronary flow velocity reserve (CFVR) is prognostic but susceptible to hemodynamic variability; we evaluated whether hyperemic coronary flow velocity (hCFV) improves risk prediction. We analyzed 246 consecutively enrolled ANOCA patients and an independent validation cohort ( n = 135). Transthoracic Doppler of the mid‐distal LAD quantified CFVR and hCFV. The primary end point was major adverse cardiovascular events (MACE). During a median follow‐up of 28.8 months, 27 patients (10.9%) experienced MACE. Both CFVR and hCFV were significantly associated with MACE. Among patients with CFVR < 2.5, hCFV ≤ 0.44 m/s independently predicted MACE (adjusted HR 6.6, p = 0.001). A combined CFVR‐hCFV scheme yielded graded risk of MACE (Group A: CFVR ≥ 2.5; Group B: CFVR < 2.5 with hCFV > 0.44 m/s; Group C: CFVR < 2.5 with hCFV ≤ 0.44 m/s), with Group C exhibiting the highest risk of MACE (35.5% vs. 6.3%, 10.5%, p < 0.01). Adding reduced hCFV to a model including clinical risk factors and CFVR improved prediction (IDI 0.05, p = 0.011; NRI 0.23, p = 0.0023) and was confirmed in the validation cohort. Reduced hCFV provides incremental prognostic value beyond CFVR and offers a practical approach to identify high‐risk ANOCA patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a cohort in Angina and nonobstructive coronary arteries (ANOCA) (n=381). Hyperemic coronary flow velocity (hCFV) assessment vs. Higher hCFV (>0.44 m/s) or CFVR alone was evaluated on Major adverse cardiovascular events (MACE) (adjusted HR 6.6, p=0.001). Reduced hyperemic coronary flow velocity independently predicted major adverse cardiovascular events in ANOCA patients with CFVR < 2.5.
Synapse has enriched 10 related papers. Consider them for comparative context: